APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: apricoxib + lapatinib + capecitabine|DRUG: placebo + lapatinib + capecitabine
Sponsor: Tragara Pharmaceuticals, Inc.